Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a historical diagnosis of type 2 diabetes mellitus (T2DM) for at least 6 months prior to the screening visit (V1).~2. Is male or female and aged from 18 to 75 years, inclusively.~3. Has a body mass index (BMI) between 20 and 45 kg/m\^2, inclusively.~4. Is experiencing inadequate glycemic control with a glycosylated hemoglobin (HbA1c) concentration between 7.0% and 10.0%, inclusively.~5. Has been treated with Metformin for at least 3 months and at a stable dose (≥1000 mg/day) for at least 8 weeks prior to Screening, unless there is documentation that the participant's current dose is his or her maximum tolerated dose (MTD) and MTD is ≤1000 mg/day.~6. Keeps constant body weight with fluctuation range no more than 10% over for at least 3 months before screening.~7. Hemoglobin levels of the participant are ≥12 g/dL (≥120 g/L) in male and≥ 10 g/dL (≥100 g/L) in female at screening visit.~8. Male serum creatinine \<1.5 mg/dL and female serum creatinine \<1.4 mg/dL, or estimated glomerular filtration rate (eGFR) \>60 ml/min/1.73m\^2 based on calculation using the Modification of Diet in Renal Disease (MDRD) approximation at Screening.~9. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.~10. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures.~Exclusion Criteria:~1. Type 1 diabetes mellitus.~2. Has received insulin, voglibose, acarbose or other oral hypoglycemic drugs (except Metformin) for accumulative total of more than 7 days within the latest 3 months prior to Visit 1.~3. Has a history of cardiovascular disease: acute myocardial infarction, class III or IV heart failure, or cerebrovascular accident (stroke) within the latest 3 months prior to Visit 1.~4. The participant's liver function is damaged and has a significant clinical sign or symptom of hepatopathy, acute or chronic hepatitis, or the value of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is 3 times more than the upper limit of normal level at Visit 1.~5. Has an active proliferative retinopathy or macular degeneration that need to have an urgent treatment in the opinion of investigators.~6. Has a frequent attack of hypoglycemia or loses consciousness due to hypoglycemia in the opinion of investigators.~7. Has one or more times ketoacidosis or hyperosmotic status/coma.~8. Is receiving long-term (\>14days) systemic glucocorticoid treatment (except the medicine: local, intraocular, inhalation or via the nose) or has received such treatment for 4 weeks at Visit 1.~9. Has a hematopathy (e.g. hemolytic anemia, drepanocytosis) that may interfere with the HbA1c test.~10. Has other liabilities (e.g. drug abuse, alcoholism or mental disorder) that may hinder the participant to follow and complete the study.~11. Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.~12. Is unsuitable for this study in the opinion of investigators.~13. Has a disease need to use other taboo or caution drugs that is not listed in this study.~14. If female, is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin + Voglibose 0.2 mg (Type: EXPERIMENTAL): Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
- Metformin + Acarbose 50 mg (Type: ACTIVE_COMPARATOR): Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).